Compare Core Scientific Inc (CORZ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Viatris Inc — how do they compare? Core Scientific Inc trades at $21.42 (market cap $6.35B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.9× Core Scientific Inc's market cap, and Viatris Inc pays a 2.95% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| CORZ | VTRS | |
|---|---|---|
Market Cap | $6.35B | $18.69B |
Sector | Technology | Health |
52-Week High | $29.16 | $17.86 |
52-Week Low | $13.55 | $9.49 |
Enterprise Value | $8.88B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $21.18, up 8.95% in the last session, amid a technical bearish trend but strong analyst optimism. The company reported Q2 2026 revenue growth and a strategic AMD partnership for AI infrastructure, though it faces significant net losses and negative cash flow. Key support lies at $18, with resistance near $21.
The outlook is mixed: bullish analyst targets near $36 suggest upside potential from AI-driven contracts, but high cash burn and persistent losses pose risks. Investors should weigh growth prospects against financial sustainability, with sentiment hinging on execution of new deals and margin improvement.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
